Top Seattle, WA Biotech Companies (29)
Don't see your company?
Create a company profile
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for pro-innovation/pro-patient policies.
ShapeTX is pioneering the field of programmable RNA medicines to repair the genetic causes of diseases. By merging innovations in AI and RNA technology to generate and analyze hundreds of billions of therapeutic possibilities, ShapeTX is developing breakthroughs in RNA editing, next-generation AAVs, and disruptive gene therapy manufacturing. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer’s, Parkinson’s, and many more.
Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe, their ingredients are authentic and labelling is accurate. Eurofins is a global leader in food, environmental, pharmaceutical and cosmetic product testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In over just 30 years, Eurofins has grown from one laboratory in Nantes, France to over 61,000 staff across a network of over 1,000 independent companies in 59 countries, operating 940 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins’ revenues have increased by 33% each year (in compound average) to reach €6.7 billion in 2021.
Resolve Therapeutics is a biotechnology company developing an exciting new biologic compound for the treatment of lupus that inhibits a key upstream step in the interferon cascade. The company is based on technology and compounds exclusively licensed from the University of Washington. The company will develop these compounds through early clinical testing and partner with a pharmaceutical company for late stage clinical development and commercialization.
AGC Biologics offers deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics (using mammalian and microbial systems), mRNA, pDNA, viral vector and cell therapy products, from pre-clinical to commercial production, including our proprietary CHEF1TM Expression System for efficient protein production with CHO cells. Our company DNA drives us to provide innovative solutions to partner with our customers in helping them reach their goals and accelerate their projects at our cGMP-compliant facilities in the US, Europe and Japan, as well as to facilitate approval and manage spending during the product lifecycle. We forge exceptionally strong partnerships with our customers and we never lose sight of our commitment to deliver reliable and compliant drug substance. Visit www.agcbio.com to learn more.
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
Kineta is a privately held emerging biotech company that was founded in 2008. Our mission is to develop novel immunotherapies that transform patients’ lives.
Lightspeed Microscopy Inc. reimagines pathology by providing a full-stack solution to nondestructively image large tissues in 3D at sub-cellular resolution. Its novel chemistry, patented high-throughput light-sheet microscope, and cloud-based AI analysis software adds a new dimension to pathology. Lightspeed, spun-out of the University of Washington and co-founded by Nick Reder in 2018, is based in Seattle, WA.
Vektor Medical, Inc is the developer of the world’s first technology to rapidly map arrhythmias anywhere in the heart using only 12-lead ECG data. The company’s smart, simple, and non-invasive cardiac arrhythmia mapping platform aims to improve first-pass ablation success, lower risks from invasive mapping and reduce procedure times.
Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, Nautilus (Nasdaq: NAUT) set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.
Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis.
Aiberry is a dynamic startup creating an innovative and practical mental health screening solution. Its platform improves efficiency and saves time for healthcare providers with cutting-edge AI technology, based on two decades of research bundled into a powerful solution that helps providers better serve their patients. Its Machine Learning (ML) pipelines are designed to eliminate biases, including those related to age, gender, sexual orientation and race. Aiberry's distinctive, multi-modal approach evaluates an individual's mental health by analyzing text, audio, and video cues during a bot-administered interview. The status quo of depression measurement requires individuals to self-rate the frequency and severity of their depression symptoms by picking a “best describes you” answer from a series of multiple-choice questions. Meanwhile, Aiberry’s app offers the option of a novel AI assessment featuring a friendly digital animation called “Botberry” that encourages users to talk about themselves in their own words.
PreemptiveAI is building the foundation model that maps human physiology/pathology and predicts health outcomes in real-time via biomedical signals from smartphones and wearable devices.
Just – Evotec Biologics is an integrated design company focused on technologies that will accelerate development of biotherapeutics and substantially reduce their manufacturing cost.
.png)
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics. Variant Bio is a Seattle-based biotech company entering a rapid growth stage having recently closed a $100mm+ Series B. The company was started because we believe that human genetics has the power to transform drug development. We are working towards developing therapies to improve global health by studying the genes of people who are outliers for medically relevant traits. To facilitate this, we have built proprietary genomics and phenotyping platforms that allow us to dramatically reduce the cost of genomic studies and identify genetically-validated targets for therapeutic development. All of our studies are co-designed with local partners: community groups, academics, and hospitals around the world, and we built Variant Bio from the ground up with ethics at its foundation. We recognize the contribution of our partners through an industry leading benefit-sharing program that dedicates 4% of our revenue and equity value to support local healthcare, sustainable development, education, research, and capacity-building initiatives. Variant Bio is an equal opportunity employer that guarantees a work environment that respects and values diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, sex, gender, gender expression, sexual orientation, age, marital status, veteran status, or disability status.
Work Your Passion. Live Your Purpose.
